Abstract
Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-α in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 358-361 |
| Number of pages | 4 |
| Journal | Neoplasma |
| Volume | 48 |
| Issue number | 5 |
| State | Published - 2001 |
| Externally published | Yes |
Keywords
- Interferon alpha
- Interleukin 12
- Melanoma
- Mice
ASJC Scopus subject areas
- Cancer Research